Glaxo investment in UK plants will boost production of innovative medicines
LONDON — Drug maker GlaxoSmithKline (GSK) on Wednesday disclosed plans to invest £275m into three of its British manufacturing sites, shrugging off Brexit worries.The investment — worth $361m — will be ploughed into facilities in Barnard Castle in northeastern England, Ware in the southeast, and Montrose in Scotland, GSK said in a statement.The move will "boost production and support delivery of its latest innovative respiratory and large molecule biological medicines", it said, adding that the "vast majority" of products will be exported globally.GSK, which already employs 6,000 staff across its nine manufacturing plants in the UK, also noted that the investment would provide new job opportunities."Today’s announcement reflects further investment to support our pharmaceutical pipeline and meet growing demand for our innovative portfolio of newly launched products," said CEO Andrew Witty, who had backed the unsuccessful "remain" campaign in Britain’s June 23 EU membership vote."It i...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.